Cargando…

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed serious threats to global health and economy, thus calling for the development of safe and effective vaccines. The receptor-binding domain (RBD) in the spike protein o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zezhong, Xu, Wei, Xia, Shuai, Gu, Chenjian, Wang, Xinling, Wang, Qian, Zhou, Jie, Wu, Yanling, Cai, Xia, Qu, Di, Ying, Tianlei, Xie, Youhua, Lu, Lu, Yuan, Zhenghong, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691975/ https://www.ncbi.nlm.nih.gov/pubmed/33247109 http://dx.doi.org/10.1038/s41392-020-00402-5

Ejemplares similares

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
por: Zhou, Yunjiao, et al.
Publicado: (2021)

A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates
por: Liu, Zezhong, et al.
Publicado: (2023)

Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD
por: Wang, Cong, et al.
Publicado: (2019)

Identification of Human Single-Domain Antibodies against SARS-CoV-2
por: Wu, Yanling, et al.
Publicado: (2020)

Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection
por: Liu, Zezhong, et al.
Publicado: (2020)

A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs
por: Liu, Zezhong, et al.
Publicado: (2022)

A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
por: Zhou, Jie, et al.
Publicado: (2022)

Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants
por: Yi, Chunyan, et al.
Publicado: (2021)

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
por: Tian, Xiaolong, et al.
Publicado: (2020)

Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine
por: Li, Chia-Jung, et al.
Publicado: (2023)

Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
por: Wang, Xinling, et al.
Publicado: (2020)

RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
por: Wang, Xinling, et al.
Publicado: (2020)

A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells
por: Wang, Xinling, et al.
Publicado: (2022)

Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit
por: Cai, Yanxing, et al.
Publicado: (2020)

Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant
por: Jia, Lina, et al.
Publicado: (2021)

Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy
por: Zhu, Xiaoyi, et al.
Publicado: (2021)

Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China
por: Wu, Fan, et al.
Publicado: (2020)

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection
por: Wang, Xinling, et al.
Publicado: (2021)

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
por: Luo, Deyan, et al.
Publicado: (2022)

IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies
por: Su, Xiaojie, et al.
Publicado: (2023)

The putative mechanism of lymphopenia in COVID-19 patients
por: Wang, Xinling, et al.
Publicado: (2022)

Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection
por: Zang, Jinkai, et al.
Publicado: (2021)

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
por: Wang, Xinling, et al.
Publicado: (2023)

Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn
por: Gong, Rui, et al.
Publicado: (2012)

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
por: Xia, Shuai, et al.
Publicado: (2019)

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
por: Ma, Hang, et al.
Publicado: (2022)

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections
por: Ying, Tianlei, et al.
Publicado: (2015)

Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody
por: Ying, Tianlei, et al.
Publicado: (2015)

SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response
por: Liu, Zheng, et al.
Publicado: (2022)

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin
por: Xia, Shuai, et al.
Publicado: (2020)

hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants
por: Liu, Junli, et al.
Publicado: (2021)

Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS)
por: Lu, Lu, et al.
Publicado: (2015)

A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome
por: Jiang, Shibo, et al.
Publicado: (2020)

IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies
por: Bi, Wenwen, et al.
Publicado: (2019)

Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines
por: Rao, Lang, et al.
Publicado: (2020)

Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
por: Li, Tingting, et al.
Publicado: (2021)

A potent human neutralizing antibody Fc-dependently reduces established HBV infections
por: Li, Dan, et al.
Publicado: (2017)

Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2
por: Gu, Chenjian, et al.
Publicado: (2021)

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants
por: Zhang, Jing, et al.
Publicado: (2022)

Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection
por: Wan, Jinkai, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ij15gju024t57m3opmom1887og